EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia

Nitin Chaudhary, Khaliqur Rahman iD, Prakhar Gupta iD, Ruchi Gupta iD, Manoj K Sarkar, Manish K Singh iD, Dinesh Chandra, Sanjeev Kumar, Rajesh Kashyap

International Journal of Laboratory Hematology · 2024

DOI: 10.1111/ijlh.14301 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Laboratory Hematology, 2024. Verfasst von Nitin Chaudhary und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, SGPGIMS, Lucknow, India. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplastic Stem Cells, Protein Kinase Inhibitors, Dipeptidyl Peptidase 4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dr. Khaliqur Rahman vide.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Leukemic stem cells (LSCs) are the transcriptionally low/silent cells which are resistant to the tyrosine kinase inhibitor. These have been found to play a pivotal role in disease relapse in chronic myeloid leukemia (CML) cases. The present study evaluated the correlation of absolute CML‐LSC count in the peripheral blood (PB) at diagnosis and achievement of major molecular response (MMR) at 12 months in patients of CML‐CP.

Methods

This was a prospective, observational, non‐interventional single center study including newly diagnosed adult (>18 yrs) CML‐CP patients. Absolute CD26 + CML‐LSC quantification was done by multiparametric flow cytometry. Patients were treated with Imatinib treatment and subsequently monitored at 3‐month intervals for BCR::ABL transcript levels. MMR was defined as a BCR::ABL1 transcript level of less than 0.1% on international scale.

Results

A total of 89 patients were enrolled in the study out of which 40.5% achieved MMR at 12 months. There was a significant difference in the median absolute CML‐LSC count of the patients who achieved MMR at 12 months as compared to those who did not (58.5 vs 368.1 cells/μL; p value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsProtein Kinase InhibitorsDipeptidyl Peptidase 4HumansMaleAdultMiddle AgedFemaleProspective StudiesAgedImatinib MesylateTreatment OutcomeFusion Proteins, bcr-ablTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

CD26chronic myeloid leukemiaflow cytometryleukemic stem cellsmajor molecular response

Substanzen

Protein Kinase InhibitorsDipeptidyl Peptidase 4Imatinib MesylateDPP4 protein, humanFusion Proteins, bcr-ablTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, SGPGIMS, Lucknow, India.

ORCID-Profile: Khaliqur Rahman, Prakhar Gupta, Ruchi Gupta, Manish K Singh

Förderung

  • Sanjay Gandhi Post Graduate Institute of Medical Sciences
  • Dr. Khaliqur Rahman vide

Zitieren

APA

Chaudhary, N., Rahman, K., Gupta, P., Gupta, R., Sarkar, M. K., Singh, M. K., Chandra, D., Kumar, S., & Kashyap, R. (2024). Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14301

Vancouver

Chaudhary N, Rahman K, Gupta P, Gupta R, Sarkar MK, Singh MK, et al. Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia. International Journal of Laboratory Hematology. 2024. doi:10.1111/ijlh.14301

BibTeX
@article{Chaudhary2024,
  author = {Chaudhary, Nitin and Rahman, Khaliqur and Gupta, Prakhar and Gupta, Ruchi and Sarkar, Manoj K and Singh, Manish K and Chandra, Dinesh and Kumar, Sanjeev and Kashyap, Rajesh},
  title = {Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia},
  journal = {International Journal of Laboratory Hematology},
  year = {2024},
  doi = {10.1111/ijlh.14301}
}
Kostenlos starten →